International research grants:
Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy (ERA-NET: Aligning national/regional translational cancer research programmes and activities TRANSCAN-2 collaborative EU; 2016-2019, J. Jakubikova (coordinator&PI))
Clonal architecture in development of MM and therapy induced intra-clonal heterogeneity in MM progression (Marie Curie Reintegration grant EU; 2015-2018, J. Jakubikova (PI))
National research grants:
Bacterial Lon protease as an emerging tool for multiple myeloma
treatment (APVV; 2022-2026, J. Jakubikova (co-PI))
Cancer immunoediting in multiple myeloma: immune checkpoints and clinical significance (APVV; 20210-2025, J. Jakubikova (PI))
Anti-myeloma activity by composite nanomaterials and its mechanism in vitro and in vivo (VEGA; 2020-2022, J. Jakubikova (PI))
Assessment of immune checkpoints in B cell malignancies (VEGA; 2020-2022, D. Cholujova (PI))
Preparation of new antibiotics and antitumor agents by manipulations of secondary metabolite genes and synthetic biology methods (APVV; 2020-2024, J. Jakubikova (co-PI))
Development of novel diagnostic and predictive high-dimensional immunophenotyping tool for hematological malignancies (Ministry of Health grant 2019/14-BMCSAV-9; 2019-2022, J. Jakubikova (PI))
Harnessing the immunological mechanisms in various subtypes of B cell lymphoma (APVV; 2020-2024, D. Cholujova (PI))
Tumor heterogeneity in multiple myeloma: evolution and clinical significance (APVV; 2017-2021, J. Jakubikova (PI))
Mechanism of anti-tumor activity of realgar nanoparticles and its synergism with anti-myeloma agents (VEGA; 2017-2019, J. Jakubikova J (PI))
The impact of tumor microenvironment and therapy on subclonal diversity in MM and WM (VEGA; 2017-2019, D. Cholujová D (PI))
Prognostic biomarker for colorectal carcinoma based on miRNA analysis and characterization of selected proteins in the circadian context (APVV, 2015-2019, J. Sedlak J (PI))